Agenus Inc. (AGEN) Shares Bought by Bank of New York Mellon Corp
Bank of New York Mellon Corp increased its stake in Agenus Inc. (NASDAQ:AGEN) by 2.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 342,133 shares of the company’s stock after buying an additional 9,403 shares during the period. Bank of New York Mellon Corp owned approximately 0.40% of Agenus worth $1,385,000 at the end of the most recent reporting period.
A number of other institutional investors also recently modified their holdings of AGEN. Fisher Asset Management LLC raised its position in shares of Agenus by 1.6% in the second quarter. Fisher Asset Management LLC now owns 93,132 shares of the company’s stock valued at $439,000 after buying an additional 1,500 shares during the period. Creative Planning raised its stake in Agenus by 2.8% in the second quarter. Creative Planning now owns 64,171 shares of the company’s stock valued at $260,000 after buying an additional 1,762 shares during the last quarter. Metropolitan Life Insurance Co. NY raised its stake in Agenus by 56.7% in the first quarter. Metropolitan Life Insurance Co. NY now owns 77,931 shares of the company’s stock valued at $324,000 after buying an additional 28,187 shares during the last quarter. Geode Capital Management LLC raised its stake in Agenus by 9.0% in the first quarter. Geode Capital Management LLC now owns 494,971 shares of the company’s stock valued at $2,059,000 after buying an additional 40,852 shares during the last quarter. Finally, venBio Select Advisor LLC raised its stake in Agenus by 9.2% in the first quarter. venBio Select Advisor LLC now owns 2,400,868 shares of the company’s stock valued at $9,988,000 after buying an additional 201,731 shares during the last quarter. 40.63% of the stock is owned by hedge funds and other institutional investors.
Shares of Agenus Inc. (NASDAQ:AGEN) traded down 3.887% on Tuesday, hitting $6.949. 718,369 shares of the stock traded hands. The stock’s market cap is $603.95 million. Agenus Inc. has a 12-month low of $2.61 and a 12-month high of $7.49. The stock has a 50-day moving average price of $6.65 and a 200 day moving average price of $4.98.
Agenus (NASDAQ:AGEN) last announced its earnings results on Thursday, July 28th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.01. Agenus had a negative net margin of 328.53% and a negative return on equity of 138.27%. The company earned $6.59 million during the quarter, compared to analysts’ expectations of $5.12 million. On average, analysts anticipate that Agenus Inc. will post ($1.27) earnings per share for the current fiscal year.
Several equities research analysts have recently issued reports on AGEN shares. Jefferies Group reissued a “buy” rating on shares of Agenus in a research report on Tuesday, August 23rd. Zacks Investment Research lowered shares of Agenus from a “buy” rating to a “hold” rating in a research report on Wednesday, September 28th. Maxim Group reissued a “buy” rating and issued a $7.00 price objective on shares of Agenus in a research report on Thursday, July 28th. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Agenus in a research report on Sunday, July 31st. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $10.25.
In related news, Director Ulf Wiinberg purchased 30,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 6th. The stock was acquired at an average cost of $6.29 per share, for a total transaction of $188,700.00. Following the completion of the acquisition, the director now owns 30,000 shares in the company, valued at approximately $188,700. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 7.60% of the company’s stock.
Agenus Inc (Agenus) is an immuno-oncology company. The Company is engaged in discovering and developing treatments for patients with cancer. Its approaches are driven by platforms and programs, which include antibody discovery platform, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage and AutoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).
Want to see what other hedge funds are holding AGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agenus Inc. (NASDAQ:AGEN).
Receive News & Ratings for Agenus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus Inc. and related companies with MarketBeat.com's FREE daily email newsletter.